Effect of dexmedetomidine supplementation for thoracoscopic surgery: A systematic review and meta-analysis

Summaries 5 min 15

Font Size

Created On: 12/05/2022

Thoracoscopic surgery is extensively utilized for the treatment of several diseases like lung cancer and esophageal cancer.

See All

Key take away

Dexmedetomidine supplementation is beneficial to enhance the analgesic efficacy for thoracoscopic surgery

Background

Thoracoscopic surgery is extensively utilized for the treatment of several diseases like lung cancer and esophageal cancer. Compared to traditional surgery, thoracoscopic surgery leads to minimized recovery duration, decreased pain and inflammatory response, and smaller incisions. Postoperative pain is common and exerts a detrimental effect on postoperative recovery. Several analgesic regimens that include regional and pharmacologic interventions (for example nerve block) have been created to manage pain that occurs after thoracoscopic surgery.

Dexmedetomidine is a short-acting α2 -adrenoceptor agonist that offers analgesia and sedation for numerous surgeries. Research has indicated that dexmedetomidine is safe and effective to enhance the analgesic efficacy when serving as an adjunctive analgesic. It also reduces the surgical stress responses in people undergoing surgery. Previous trials depicted that dexmedetomidine is beneficial for pain mitigation, minimized analgesic-related adverse events, and exhibited opioid-sparing features.

RATIONALE BEHIND RESEARCH

For thoracoscopic surgery, the effectiveness of dexmedetomidine supplementation has not been well-documented. Numerous studies have been published. However, the findings were contradictory. Therefore, this study was carried out to explore the analgesic efficacy of dexmedetomidine supplementation for thoracoscopic surgery.

OBJECTIVE

This systematic review and meta-analysis aimed to investigate the influence of dexmedetomidine on thoracoscopic surgery

Method

Literature search

With the aid of databases such as Cochrane Library, EBSCO, Web of Science, Embase, and PubMed, the literature search was performed. Using the keywords “dexmedetomidine”, and “thoracoscopic” or “thoracoscopy”, the electronic search strategy was performed. The reference lists of screened full-text studies were also verified to find out other eligible trials.

Inclusion criteria

Studies were included in this systematic review if:

the study was a randomized controlled trial (RCT)
the intervention was intravenous dexmedetomidine supplementation versus no dexmedetomidine
the patients underwent thoracoscopic surgery

Study selection and Data extraction

Articles meeting the inclusion criteria were retrieved. Extraction of the information like body mass index, sex, age, number of patients, author, American Society of Anesthesiologists (ASA) and detail methods in each group was done. To describe a patient’s preoperative medical condition, the ASA Physical Status Classification System is extensively used. Data extraction was performed independently by 2 researchers and contradictions were solved by agreement.

Data and Statistical Analysis

For continuous outcomes (hospital stay, blood pressure, mean heart rate, analgesic consumption, and pain scores), the standard mean difference (SMD) with 95% confidence interval (CI) was assessed while for dichotomous outcomes (intensive care unit [ICU] stay), the relative risk with 95% CI was estimated. The utilization of the random-effects model was done irrespective of heterogeneity. Notably, I2 > 50% indicated significant heterogeneity that was reported using the I2 statistic.

Possible heterogeneity sources were searched by excluding 1 study in turn for meta-analysis or executing subgroup analysis whenever profound heterogeneity was present. Utilizing the Review Manager Version 5.3, all the statistical analyses were executed.

Risk of Bias and Quality assessment

Evaluation of the publication bias was not done due to the confined number (< 10) of incorporated studies. Utilizing the Jadad scale (score varies from 0 to 5 points), the methodological quality of the incorporated studies was independently investigated. In total, there are three items for the Jadad scale: (a) dropouts and withdrawals (0-1 points), (b) blinding (0-2 points), and (c) randomization (0-2 points). An article with a Jadad score ≤2 was deemed to be of low quality while an article with a Jadad score≥3 was deemed to be of high quality.

Study outcomes

Pain scores were the major outcome ascertained
Hospital stay, ICU stay, mean heart rate and blood pressure, and analgesic consumption were the secondary outcomes ascertained

Result

Outcomes

Study and participant characteristics:

A total of 6 RCTs including 510 patients were incorporated in the meta-analysis
Dexmedetomidine was utilized while surgery or prior to the anesthesia
Notably, 3 studies out of 6 studies reported pain scores. Analgesic intake was reported by 3 studies, blood pressure and mean heart rate was reported by 4 studies, ICU stay was reported by 3 studies, and hospital stay was reported by 3 studies

Study quality:

The Jadad scores of the 6 incorporated studies varied from 3 to 5, and according to the quality assessment, all the 6 studies were found to be of high-quality

Effect of intervention on the outcome:

When compared to the control group, dexmedetomidine supplementation for thoracoscopic surgery resulted in considerably lowered pain scores (SMD = −1.50), mean heart rate (SMD = −0.41), anesthetic intake (SMD = −3.91), and the risk ratio (RR) of ICU stay (RR = 0.39)
No impact on mean blood pressure (SMD = −0.07) or hospital stay (SMD = −0.61) was observed

Conclusion

For the treatment of lung cancer, thoracoscopic surgery has been broadly utilized due to its minimal invasion, decreased hospital stay, and minimized postoperative pain when compared to open thoracotomy. For anesthesiologists and patients, the postoperative pain management, specifically early postoperative pain, yet remains a significant area of concern. Opioids are important during surgery. However, owing to the occurrence of adverse events like respiratory depression, opioid-elicited nausea, and delayed recovery from general anesthesia, various methodologies are prepared to lower opioid intake.

The use of intraoperative dexmedetomidine has been reported to enhance postoperative analgesic effects. It depicted anxiolytic, sedative and pain-relieving effects, and prevented respiratory depression and the suppressive effect of sympathetic stimulation as an adjuvant to general anesthesia. This meta-analysis incorporated 510 patients and 6 RCTs. The findings exhibited that intravenous dexmedetomidine was linked to a considerable reduction in pain scores, anesthetic intake, the RR of ICU stay and mean heart rate following thoracoscopic surgery.

However, it did not impact hospital stay or mean blood pressure. Additionally, dexmedetomidine aided in decreasing the stress response and maintaining the cardiovascular system's stability. Both epinephrine and norepinephrine are lowered by intraoperative infusion of dexmedetomidine. Dexmedetomidine has hypnotic, anxiolytic, and analgesic effects and can reduce the release of catecholamines. There is considerable heterogeneity regarding the sensitivity analysis. There may be various reasons for heterogeneity.

Primarily, various methods and doses of dexmedetomidine supplementation may cause some bias. For example, dexmedetomidine was utilized prior to anesthesia or during operation. Secondly, dexmedetomidine was employed as the adjunct to various drugs like sevoflurane and oxycodone, which may lead to several analgesic effects. Thirdly, different surgeries elicit different intensities of pain that might influence the pooling results.

Limitations

This study is based on just 6 RCTs, and 3 of them have a quite small sample size (n<100)
Compared with larger samples, the overestimation of the intervention effect was more probable in smaller trials
The combination, methodologies, and doses of anesthetic agents in incorporated RCTs are distinct. This might affect the pooling results
Thoracoscopic surgeries are executed for several diseases and operation techniques

Clinical take-away

Intravenous dexmedetomidine was linked with a remarkable reduction in pain scores, anesthetic consumption, and the RR of ICU stay. Hence, clinicians should consider dexmedetomidine supplementation in patients who underwent thoracoscopic surgery, as supported by the findings of a recent analysis.